Reply

Hugh A. Sampson; Roy Gerth Van Wijk; Carsten Bindslev-Jensen; Scott H. Sicherer; Suzanne Teuber; Wesley Burks; Anthoney E. Dubois; Kirsten Beyer; Philippe A. Eigenmann; Jonathan M. Spergel; Thomas Werfel

doi:10.1016/j.jaci.2013.04.041

Reply

Hugh A. Sampson, Roy Gerth Van Wijk, Carsten Bindslev-Jensen, Scott H. Sicherer, Suzanne Teuber, Wesley Burks, Anthoney E. Dubois, Kirsten Beyer, Philippe A. Eigenmann, Jonathan M. Spergel, Thomas Werfel

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	502-503
Number of pages	2
Journal	Journal of Allergy and Clinical Immunology
Volume	132
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2013.04.041
State	Published - Aug 2013

Access to Document

10.1016/j.jaci.2013.04.041

Cite this

@article{2f1ad753e998436796160a61fa75f798,

title = "Reply",

author = "Sampson, {Hugh A.} and {Van Wijk}, {Roy Gerth} and Carsten Bindslev-Jensen and Sicherer, {Scott H.} and Suzanne Teuber and Wesley Burks and Dubois, {Anthoney E.} and Kirsten Beyer and Eigenmann, {Philippe A.} and Spergel, {Jonathan M.} and Thomas Werfel",

note = "Funding Information: Disclosure of potential conflict of interest: H. A. Sampson has received consultancy fees from Allertein Therapeutics ; is employed by the Icahn School of Medicine at Mount Sinai; has received research support from the National Institute of Allergy and Infectious Disease (NIAID) , the Food Allergy Initiative , and the Thermo Fisher Scientific ; and receives royalties from UpToDate and Elsevier . R. G. van Wijk has received consultancy fees from MSD, HAL, and Crucell ; has received research support from NWO, STW, Novartis, Biomay, and DBV ; has received lecture fees from Allergopharma ; has received payment for manuscript preparation from Chiesi ; and receives royalties from de Tijdstroom and Bohn, Stafleu, van Loghum . C. Bindslev-Jensen has received travel support from the European Academy of Allergology and Clinical Immunology (EAACI) ; and has received lecture fees from MSD and Thermo Fisher Scientific . S. H. Sicherer has received consultancy fees from the Food Allergy Initiative . S. Teuber has received consultancy fees from Sanofi-Aventis and the International Food Information Council and has received lecture fees from the Kaiser Permanente Foundation and California Society of Allergy, Asthma & Immunology . W. Burks has received research support from the National Institutes of Health (NIH) ; was on the American Academy of Allergy, Asthma & Immunology (AAAAI) Board; was a member of the NIH Study Section (HAI); was on the US Food and Drug Administration (FDA) Food Advisory Committee; was on the Merck US Allergy Immunotherapy Allergist Advisory Board; is on the Food Allergy & Anaphylaxis Network Research Advisory Board; has received consultancy fees from ActoGeniX, Dow AgroSciences, McNeill Nutritionals, Merck, Novartis, Sanofi-Aventis, Schering Plough, and Unilever ; was employed by Duke University and is employed by UNC Children's Hospital; has received research support from the NIH and Wallace Research Foundation ; has received lecture fees from Abbott Laboratories and Mylan Specialty ; owns multiple patents; has received payment for developing educational presentations from Current Views 2012 ; and is a minority stockholder in Allertein and Mastcell Pharmaceuticals. A. E. Dubois has received travel support from the EAACI/AAAAI ; is on the ALK-Abell{\'o} ABU advisory board; has received research support from ALK-Abell{\'o} ABU EAI research and Thermo Fisher Scientific ; has received payment for the development of educational presentations from Mead Johnson ; and has received travel support as a speaker from the EAACI and FAAM, PAAM . K. Beyer has received research support from the European Union German Research Foundation, the Foundation for the Treatment of Peanut Allergy, and Danone ; has received consultancy fees from Danone, Novartis, ALK-Abell{\'o}, and Meda Pharma ; and has received lecture fees from Danone, Phadia, InfectoPharm, CSL Behring, Novartis, UCB, Meda Pharma, Med Update, Allergopharma, and Thermo Fisher Scientific . P. A. Eigenmann has received travel support from the EAACI ; has received consultancy fees from DBV Technologies, Danone, Nestl{\'e}, and ALK-Abell{\'o} ; has received research support from LETI and Nestl{\'e} ; has received lecture fees from Stallergenes, Sodilac, and Phadia ; has received royalties from UpToDate and Elsevier ; and has stock/stock options in DBV Technologies. J. M. Spergel is on the DBV Board; has received research support from Nutricia and the Department of Defense ; has received lecture fees from MEI and Nutricia ; receives royalties from UpToDate ; has received payment for the development of educational presentations from MEI ; and has stock/stock options in DBV. T. Werfel declares he has no relevant conflicts of interest. ",

year = "2013",

month = aug,

doi = "10.1016/j.jaci.2013.04.041",

language = "English",

volume = "132",

pages = "502--503",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Reply

AU - Sampson, Hugh A.

AU - Van Wijk, Roy Gerth

AU - Bindslev-Jensen, Carsten

AU - Sicherer, Scott H.

AU - Teuber, Suzanne

AU - Burks, Wesley

AU - Dubois, Anthoney E.

AU - Beyer, Kirsten

AU - Eigenmann, Philippe A.

AU - Spergel, Jonathan M.

AU - Werfel, Thomas

N1 - Funding Information: Disclosure of potential conflict of interest: H. A. Sampson has received consultancy fees from Allertein Therapeutics ; is employed by the Icahn School of Medicine at Mount Sinai; has received research support from the National Institute of Allergy and Infectious Disease (NIAID) , the Food Allergy Initiative , and the Thermo Fisher Scientific ; and receives royalties from UpToDate and Elsevier . R. G. van Wijk has received consultancy fees from MSD, HAL, and Crucell ; has received research support from NWO, STW, Novartis, Biomay, and DBV ; has received lecture fees from Allergopharma ; has received payment for manuscript preparation from Chiesi ; and receives royalties from de Tijdstroom and Bohn, Stafleu, van Loghum . C. Bindslev-Jensen has received travel support from the European Academy of Allergology and Clinical Immunology (EAACI) ; and has received lecture fees from MSD and Thermo Fisher Scientific . S. H. Sicherer has received consultancy fees from the Food Allergy Initiative . S. Teuber has received consultancy fees from Sanofi-Aventis and the International Food Information Council and has received lecture fees from the Kaiser Permanente Foundation and California Society of Allergy, Asthma & Immunology . W. Burks has received research support from the National Institutes of Health (NIH) ; was on the American Academy of Allergy, Asthma & Immunology (AAAAI) Board; was a member of the NIH Study Section (HAI); was on the US Food and Drug Administration (FDA) Food Advisory Committee; was on the Merck US Allergy Immunotherapy Allergist Advisory Board; is on the Food Allergy & Anaphylaxis Network Research Advisory Board; has received consultancy fees from ActoGeniX, Dow AgroSciences, McNeill Nutritionals, Merck, Novartis, Sanofi-Aventis, Schering Plough, and Unilever ; was employed by Duke University and is employed by UNC Children's Hospital; has received research support from the NIH and Wallace Research Foundation ; has received lecture fees from Abbott Laboratories and Mylan Specialty ; owns multiple patents; has received payment for developing educational presentations from Current Views 2012 ; and is a minority stockholder in Allertein and Mastcell Pharmaceuticals. A. E. Dubois has received travel support from the EAACI/AAAAI ; is on the ALK-Abelló ABU advisory board; has received research support from ALK-Abelló ABU EAI research and Thermo Fisher Scientific ; has received payment for the development of educational presentations from Mead Johnson ; and has received travel support as a speaker from the EAACI and FAAM, PAAM . K. Beyer has received research support from the European Union German Research Foundation, the Foundation for the Treatment of Peanut Allergy, and Danone ; has received consultancy fees from Danone, Novartis, ALK-Abelló, and Meda Pharma ; and has received lecture fees from Danone, Phadia, InfectoPharm, CSL Behring, Novartis, UCB, Meda Pharma, Med Update, Allergopharma, and Thermo Fisher Scientific . P. A. Eigenmann has received travel support from the EAACI ; has received consultancy fees from DBV Technologies, Danone, Nestlé, and ALK-Abelló ; has received research support from LETI and Nestlé ; has received lecture fees from Stallergenes, Sodilac, and Phadia ; has received royalties from UpToDate and Elsevier ; and has stock/stock options in DBV Technologies. J. M. Spergel is on the DBV Board; has received research support from Nutricia and the Department of Defense ; has received lecture fees from MEI and Nutricia ; receives royalties from UpToDate ; has received payment for the development of educational presentations from MEI ; and has stock/stock options in DBV. T. Werfel declares he has no relevant conflicts of interest.

PY - 2013/8

Y1 - 2013/8

UR - http://www.scopus.com/inward/record.url?scp=84881184662&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2013.04.041

DO - 10.1016/j.jaci.2013.04.041

M3 - Letter

C2 - 23763978

AN - SCOPUS:84881184662

SN - 0091-6749

VL - 132

SP - 502

EP - 503

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -